JERSEY CITY, N.J.

新泽西州泽西市

,

，

Oct. 8, 2026

2026年10月8日

/PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that

/美通社/ -- 领先的资本市场及机构执行服务提供商 WallachBeth Capital LLC 宣布，

bioAffinity Technologies, Inc.

bioAffinity 技术公司

(NASDAQ:

（纳斯达克：

BIAF

BIAF

, BIAFW)

，BIAFW）

a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules..

一家致力于开发用于肺部疾病早期检测和监测的非侵入性医疗解决方案的生物技术公司，已与一家机构投资者签订最终协议，根据纳斯达克规则下的按市价定价注册直接发行，以每股6.122美元（或每份预融资认股权证6.115美元）的购买价格出售普通股（或替代的预融资认股权证）。

Additionally in a concurrent private placement the Company will sell warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants will have an exercise price of $0.007 per share of common stock, and the warrants will have an exercise price of $6.122 per share, will be exercisable following stockholder approval, and will expire five years from the date of stockholder approval.

此外，在同步进行的私募配售中，公司将出售认股权证，允许持有人以每股6.122美元的行权价购买总计最多980,072股普通股。预付资金认股权证的行权价为每股普通股0.007美元，而普通认股权证的行权价为每股6.122美元；该等认股权证将在获得股东批准后生效，并自股东批准之日起五年后到期。

The closing of the offering is expected to occur on or about October 9, 2026, subject to the satisfaction of customary closing conditions..

本次发行的交割预计将于2026年10月9日或前后进行，但须满足惯例交割条件。

WallachBeth Capital, LLC is acting as sole placement agent for the offering.

WallachBeth Capital, LLC 担任本次发行的独家配售代理。

The gross proceeds to the Company from the offering are expected to be approximately $4 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital, to support expected growing sales for .

在扣除配售代理费用及公司应支付的其他发行费用之前，公司从本次发行中获得的总收益预计约为400万美元。公司拟将本次发行的净收益用于营运资金，以支持预期的销售增长。

CyPath® Lung

CyPath® Lung

, its noninvasive test for lung cancer, and general corporate purposes.

、其肺癌无创检测业务，以及一般公司用途。

The common stock described above is being offered by the Company pursuant to a 'shelf' registration statement on Form S-3 (File No. 333-275608) previously filed with the U.S. Securities and Exchange Commission ('SEC'), under the Securities Act of 1933, as amended (the 'Securities Act'), and declared effective by the SEC on November 27, 2023.

上述普通股正由本公司根据先前向美国证券交易委员会（“SEC”）提交的S-3表格货架注册声明（档案号：333-275608）进行发售，该注册声明依据经修订的《1933年证券法》（“《证券法》”）提交，并已于2023年11月27日获SEC宣布生效。

The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement describing the terms of the proposed registered direct offering and accompanying prospectus will be filed with the SEC.

普通股的发售仅通过构成生效注册声明一部分的招股说明书（包括招股说明书补充文件）进行。描述拟议注册直接发行条款的招股说明书补充文件及随附的招股说明书将提交给美国证券交易委员会（SEC）。

Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at .

招股说明书补充文件及随附招股说明书的电子版可在美国证券交易委员会（SEC）网站获取（如有）。

https://www.sec.gov

https://www.sec.gov

or by contacting WallachBeth Capital, LLC, via email at

或通过电子邮件联系 WallachBeth Capital, LLC，邮箱地址为

[email protected]

[email protected]

, by calling +1-646-237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

，通过拨打 +1-646-237-8585，或通过普通邮件寄至 WallachBeth Capital LLC（收件人：资本市场部），地址为 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA。

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，在任何司法管辖区，若根据该辖区的证券法在注册或资格认定之前进行此类要约、招揽或销售属于违法行为，则不会在该辖区进行这些证券的任何销售。

About WallachBeth Capital LLC:

关于WallachBeth Capital LLC：

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's..

WallachBeth Capital 为医疗健康领域提供全面的资本市场和投资银行服务，将企业客户与领先机构相连接，助力发行人和投资者实现其财务目标。该公司的经验涵盖首次公开发行（IPO）、增发、私募股权投资 PIPE、私人交易以及自动柜员机销售计划（ATM）。

Forward-Looking Statement

前瞻性声明

Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.

本新闻稿中的某些陈述构成联邦证券法意义上的“前瞻性陈述”。诸如“可能”、“或许”、“将”、“应当”、“相信”、“预期”、“预计”、“估计”、“继续”、“预测”、“预报”、“规划”、“打算”等类似表述，或涉及意图、信念或当前预期的陈述，均属于前瞻性陈述。

These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to close the offering when anticipated, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K.

这些前瞻性陈述受各种风险和不确定性的影响，其中许多难以预测，可能导致实际结果与当前预期和假设存在重大差异，或与任何前瞻性陈述中明示或暗示的内容存在重大差异。可能导致实际结果与当前预期存在重大差异的重要因素包括（但不限于）公司能否按预期完成发行，以及公司在截至2025年12月31日的年度10-K表年报及其后续向美国证券交易委员会（SEC）提交的文件（包括后续的10-Q表和8-K表定期报告）中讨论的其他因素。

Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements.

此类前瞻性陈述基于作出该等陈述时存在的事实和状况，以及对未来事实和状况的预测。尽管本公司认为这些前瞻性陈述是合理的，但本新闻稿的读者被提醒不要过度依赖任何前瞻性陈述。

The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws..

本新闻稿中的信息仅截至本新闻稿发布之日提供，除非适用证券法另有要求，公司不承担任何更新与本新闻稿所讨论事项相关的任何前瞻性陈述的义务。

SOURCE WallachBeth Capital LLC

来源：WallachBeth Capital LLC

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示